Biopharmaceutical company Infinity Pharmaceuticals, Inc. (INFI) announced Tuesday the appointment of Robert Ilaria, Jr. as Chief Medical Officer. In addition, Brian Schwartz will be transitioning from his role as Consulting Chief Physician to the Infinity Board of Directors.
Ilaria joins Infinity from Bristol Myers Squibb where he was most recently the CTLA-4 Development Program Leader. He was previously Executive Medical Director, Global Clinical Research and Development at Celgene and Program Lead Physician for the PD-1 inhibitor tislelizumab partnership with BeiGene.
Schwartz has over 25 years of experience as a drug development expert in pharmaceutical and biotechnology industries and has served as Infinity's consulting Chief Physician since early 2020.
He was previously at ArQule for 10 years where he served as CMO prior to the acquisition by Merck & Co. of ArQule in late 2019. He has also served in senior leadership roles at Ziopharm Oncology, Inc., Bayer AG, and LeoLabs, Inc.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.